STOCK TITAN

Evotec SE - EVO STOCK NEWS

Welcome to our dedicated news page for Evotec SE (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec SE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evotec SE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evotec SE's position in the market.

Rhea-AI Summary
Evotec and Novo Nordisk announce LAB eN², a translational drug discovery accelerator focused on cardiometabolic diseases. Four academic institutions, including Harvard University and Mass General Brigham, have already signed on to participate. LAB eN² aims to accelerate the translation of academic ideas into therapeutic product candidates. It will provide funding, scientific expertise, and technology to advance concepts through pre-clinical proof of concept. Successful candidates may be selected for further investment and development by Novo Nordisk. The prevalence of cardiometabolic diseases is increasing, creating a significant need for new therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
-
Rhea-AI Summary
Evotec SE announces financial results for H1 2023, with group revenues increasing by 14% to €383.8m. Adjusted Group EBITDA totaled €26.1m. New alliances and collaborations reflect success of growth strategy. Business outlook for FY 2023 confirmed with revenues expected to be in a range of €750-790m and adjusted Group EBITDA guidance range between €60-80m. Cyber-incident in Q2 temporarily reduced revenue growth. Unpartnered research and development expenses expected to be in a range of €60-70m.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
none
-
Rhea-AI Summary
Evotec SE to announce financial results for first half-year of 2023 on August 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
partnership
-
Rhea-AI Summary
Evotec SE's subsidiary, Just - Evotec Biologics, has been awarded a contract worth up to $74 million by the U.S. Department of Defense (DOD) to develop monoclonal antibody-based drug prototypes for orthopoxviruses. The contract includes antibody discovery, development, and clinical trial services. Evotec will leverage its technology platform, J.DESIGN, and its pre-clinical and clinical biologics development capabilities to accelerate the development of safe and efficacious medical countermeasures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none
Evotec SE

OTC:EVO

EVO Rankings

EVO Stock Data

2.60B
145.80M
1.61%
0.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Hamburg

About EVO

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists.